SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VaxGen Inc.-The 1st AIDS Vaccine in Phase 3 HumanTrials
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Manfred Sondermann who wrote (66)7/7/1999 5:16:00 PM
From: glen   of 250
 
AIDSVAX was developed by Genentech beginning in 1984 and was spun out in 1995 as a separate company, with Genentech holding a 25% interest. Since the IPO increased the outstanding shares by 3.1 million, this percentage has decreased, but not due to any selling of shares by Genentech.

Genentech has all of the infrastructure in place to efficiently manufacture the vaccine, and thus affords VaxGen not having to tie up unnecessary amounts of enormous capital. If AIDSVAX successfully obtains FDA approval, the relatively low overhead structure that VaxGen will have will provide tremendous leverage for a what would then become a very highly profitable company. The growth potential on small VaxGen will be huge.

If VaxGen succeeds in bringing AIDSVAX to market, everyone is a winner. Not only shareholders in both VaxGen and Genentech, but the rest of the world's population.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News